This study is completed in the United States and in Canada. It is testing RO4917838 for OCD.
OCDDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether RO4917838 may be useful for adults experiencing ocd.
What would participation involve?
Participants may receive RO4917838, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Canada and in the United States.
Who is it mainly for?
This study appears to be mainly for adults with ocd.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: December 31, 2012
Recruitment status
Completed
Enrollment listed in the registry
99
Sponsor
Hoffmann-La Roche
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT01674361
Official title
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate Efficacy and Safety of RO4917838 in Combination With Selective Serotonin Reuptake Inhibitors in Patients With Obsessive Compulsive Disorder
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Canada · 7 sites
Chokka Center for Integrative Health
Edmonton, Alberta
Site status: Not listed — confirm with the team
Okanagan Clinical Trials
Kelowna, British Columbia
Site status: Not listed — confirm with the team
True North Clinical Research-Halifax
Halifax, Nova Scotia
Site status: Not listed — confirm with the team
True North Clinical Research Kentville
Kentville, Nova Scotia
Site status: Not listed — confirm with the team
McMaster University - MacAnxiety Research Centre
Hamilton, Ontario
Site status: Not listed — confirm with the team
Sunny Johnson Medical Research Associates Inc.; Medical Research Associates
Mississauga, Ontario
Site status: Not listed — confirm with the team
START Clinic for Mood & Anxiety Disorders
Toronto, Ontario
Site status: Not listed — confirm with the team
United States · 27 sites
Excell Research
Oceanside, California
Site status: Not listed — confirm with the team
Stanford University School of Medicine
Stanford, California
Site status: Not listed — confirm with the team
Yale University School of Medicine; Neuroscience Research Training Program
New Haven, Connecticut
Site status: Not listed — confirm with the team
Compass Research North, LLC
Leesburg, Florida
Site status: Not listed — confirm with the team
Medical Research Group of Central Florida
Orange City, Florida
Site status: Not listed — confirm with the team
University of South Florida
St. Petersburg, Florida
Site status: Not listed — confirm with the team
University of South Florida
Tampa, Florida
Site status: Not listed — confirm with the team
iResearch Atlanta
Decatur, Georgia
Site status: Not listed — confirm with the team
Carman Research
Smyrna, Georgia
Site status: Not listed — confirm with the team
Uni of Chicago; Centre For Advanced Medicine
Chicago, Illinois
Site status: Not listed — confirm with the team
Louisiana Research Associates
New Orleans, Louisiana
Site status: Not listed — confirm with the team
Massachusetts General Hospital - East
Boston, Massachusetts
Site status: Not listed — confirm with the team
Boston Clinical Trials
Boston, Massachusetts
Site status: Not listed — confirm with the team
Ambulatory Research Center (ARC), Department of Psychiatry
Minneapolis, Minnesota
Site status: Not listed — confirm with the team
Precise Research Centers
Flowood, Mississippi
Site status: Not listed — confirm with the team
St Louis Clinical Trials
St Louis, Missouri
Site status: Not listed — confirm with the team
Mount Sinai School of Medicine; Department of Psychiatry
New York, New York
Site status: Not listed — confirm with the team
Medical Research Network - New York
New York, New York
Site status: Not listed — confirm with the team
Finger Lakes Clinical Research
Rochester, New York
Site status: Not listed — confirm with the team
North Star Research
Middleburg Heights, Ohio
Site status: Not listed — confirm with the team
Ips Research Company
Oklahoma City, Oklahoma
Site status: Not listed — confirm with the team
Keystone Clinical Studies, LLC
Norristown, Pennsylvania
Site status: Not listed — confirm with the team
Butler Hospital - Department of Psychiatry and Human Behavior
Providence, Rhode Island
Site status: Not listed — confirm with the team
Clinical Neuroscience Solutions,Inc
Memphis, Tennessee
Site status: Not listed — confirm with the team
FutureSearch Trials, LP
Austin, Texas
Site status: Not listed — confirm with the team
Eastside Therapeutic Resource
Kirkland, Washington
Site status: Not listed — confirm with the team
Dean Foundation
Middleton, Wisconsin
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT01674361. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with ocd. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving Bitopertin, Placebo, SSRI. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with ocd; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Hoffmann-La Roche, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
